Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q4 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.9% year on year to $194.8 million. On the other hand, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results